CeNeS (CEN.L) - valedictory results and recommended acquisition by Paion
Apr 10, 2008
CeNeS Pharmaceuticals (CEN.L) - fund raising bites the dilution bullet
Aug 01, 2007
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) - publication to confirm that CNS 7056 achieves deep sedation
Jun 25, 2007
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) - further analysis strengthens package for licensees
Jun 11, 2007
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) - FDA approves IND on Lead Product M6G
Apr 27, 2007
CeNeS Pharmaceuticals (CEN.L) - preliminary results
Mar 28, 2007
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) - secondary M6G trial data provides additional support
Mar 14, 2007
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) - M6G hits the target profile
Feb 21, 2007
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) - fund raising secures progress beyond Q1 07
Dec 07, 2006
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) - interim update
Oct 02, 2006
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) - cost-sharing partnership for CNS 5161
Aug 04, 2006
| Click for PDF
CeNeS Pharmaceuticals (CEN.L) -
May 30, 2006
| Click for PDF
Disclaimer
Objective Capital is a provider of corporate research. Our research reports provide information, analysis, and estimates and may reference our opinion on the value of highlighted companies. Objective Capital is not registered by any financial authority, and does not provide or purport to provide investment advice or recommendations of any description.
The information in this report is designed to present the opinion of Objective's analysts and what they believe to be the objective prospects of the highlighted company. Where reference is made to estimates of value or relative value of a specific company these are based on standard analysis assuming an "average" investor. There is no guarantee that these estimates are reliable or will eventuate. They should not be relied upon in forming specific investment decisions and readers should seek advice specific to their situation and investment requirements from a person authorized under the Financial Services and Markets Act 2000, before entering into any investment agreement.
Objective Capital's detailed reports are only available to ordinary business investors, market counterparties, high net-worth and sophisticated individual investors.
This report does not constitute an offer or invitation to purchase or acquire any shares in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares in any company.
The information in this report is believed to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise.
Objective Capital (including its Directors, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules. Objective Capital and its analysts are bared from trading in the shares of companies on which Objective Capital provides coverage.
You are reminded that the value of shares in any company may go up or down. Past performance is not necessarily a guide to future performance.
By accessing this report, you confirm that you have read and accepted this disclaimer. If you are in any doubt as to whether you are able to access this report from your jurisdiction please consult with your financial advisors before continuing.
